• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BOSTON SCIENTIFIC - GALWAY SYNERGY¿; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BOSTON SCIENTIFIC - GALWAY SYNERGY¿; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number UNK776
Device Problem Peeled/Delaminated (1454)
Patient Problem No Consequences Or Impact To Patient (2199)
Event Type  malfunction  
Manufacturer Narrative
Fujimoto, yoshihie, et.Al., 'delamination of novel ultrathin bioabsorbable abluminal polymer of platinum chromium everolimus-eluting stent', cardioasc interv and ther 2018 33:97-98, https://doi.Org/10.1007/s12928-016-0442-9.Device is a combination product.(b)(6).(b)(4).Device evaluated by mfr: the complaint device was not received for analysis.The investigation conclusion is operational context as the product meets the design & manufacture specification but due to anatomical/procedural factors encountered during the procedure, performance was limited.(b)(4).
 
Event Description
It was reported via literature that polymer delamination occurred.The 90% stenosed target lesion was located in the severely calcified mid-left anterior descending coronary artery (lad).After predilatation, delivery of a 24mm synergy stent in the mid-lad was attempted.However, it would not advance to the target lesion in the mid-lad even with the a non-bsc guide extension catheter.Rotational atherectomy was performed.A durable polymer everolimus-eluting stent was then deployed.The final angiogram showed a good result.Scanning electron microscopy demonstrated damage to the bioabsorbable polymer of the synergy stent; most of the damage was delamination of abluminal polymer.It was concluded that delamination of abluminal bioabsorbable polymer may occur more easily and severely when it is delivered through a calcified coronary artery.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
SYNERGY¿
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BOSTON SCIENTIFIC - GALWAY
Manufacturer (Section G)
BOSTON SCIENTIFIC - GALWAY
Manufacturer Contact
sonali arangil
one scimed place
maple grove, MN 55311
7634941700
MDR Report Key7587876
MDR Text Key110707227
Report Number2134265-2018-05126
Device Sequence Number1
Product Code NIQ
Combination Product (y/n)N
PMA/PMN Number
SIMILAR
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,foreig
Reporter Occupation Physician
Type of Report Initial
Report Date 05/15/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received06/11/2018
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Model NumberUNK776
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received05/15/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage N
Patient Sequence Number1
Patient Age76 YR
-
-